9 citations
,
July 2018 in “European Journal of Dermatology” Brodalumab effectively treated a man's severe hand and foot psoriasis.
3 citations
,
July 2022 in “European Journal of Dermatology” In this study, researchers using multistate modeling reported that patients with psoriasis treated with brodalumab had a higher probability of achieving and maintaining a therapeutic response compared to those treated with ustekinumab over 52 weeks, based on absolute PASI measurements.
1 citations
,
May 2023 in “Prospects in Pharmaceutical Sciences” This study reviews current treatments for alopecia areata, highlighting that despite various options like corticosteroids and immunosuppressives, their limited efficacy and potential side effects are challenges, while targeting specific cytokines has shown promise except with TNF inhibitors, which may worsen the condition.
July 2022 in “European Journal of Dermatology” In this study, researchers found that patients with psoriasis had a higher probability of achieving and maintaining a clinical response using brodalumab compared to ustekinumab over 52 weeks, as measured by a multistate modelling approach based on absolute PASI scores.
July 2022 in “European Journal of Dermatology” This study found that using a method based on absolute PASI, patients with psoriasis receiving brodalumab had a higher probability of achieving and maintaining a treatment response over 52 weeks compared to those receiving ustekinumab.